Liver Cancer Market Report 2025

The liver cancer market size has grown rapidly in recent years. It will grow from $2.94 billion in 2024 to $3.37 billion in 2025 at a compound annual growth rate (CAGR) of 14.5%. The growth during the historic period can be attributed to the increasing global incidence of liver cancer, the rising prevalence of hepatitis B and C infections, higher rates of non-alcoholic fatty liver disease, government initiatives encouraging early diagnosis, and growing awareness about liver health.

The liver cancer market size is expected to see rapid growth in the next few years. It will grow to $5.75 billion in 2029 at a compound annual growth rate (CAGR) of 14.3%. The growth during the forecast period can be attributed to the expanding geriatric population, higher healthcare spending, increasing demand for minimally invasive treatments, a rise in specialty clinics, and the growth of medical tourism. Key trends during this period include advancements in diagnostic technologies, the development of targeted therapies, the introduction of combination therapies, technological innovations in surgical procedures, and progress in radiotherapy techniques.

The growing consumption of alcohol is expected to drive the expansion of the liver cancer market. Alcohol consumption, typically measured by its quantity and frequency, has been rising as it helps people relieve daily stress, fosters social interaction, and enhances relaxation, with its promotion in media and increased accessibility in various settings. However, excessive alcohol intake can lead to liver cirrhosis, inflammation, and DNA damage, which increases the risk of liver cancer by encouraging abnormal cell growth. For example, in March 2023, the National Drugs Library, an Ireland-based data collection organization, reported that the average alcohol consumption for individuals aged 15 and older increased to 10.2 liters of pure alcohol per capita in 2022, reflecting a 7.6% rise from 2021. This increase in alcohol consumption is contributing to the growth of the liver cancer market.

Leading companies in the liver cancer market are focusing on developing advanced therapy devices, specifically transcatheter arterial chemoembolization (TACE), to improve treatment precision, patient outcomes, and reduce side effects. TACE is a minimally invasive procedure that delivers chemotherapy directly to a liver tumor while blocking its blood supply to increase the treatment’s effectiveness. For example, in November 2023, Terumo Corporation, a Japan-based medical technology company, launched two innovative therapy devices, Occlusafe and LifePearl, to assist in the management of liver cancer. These devices are designed to improve the treatment of hepatocellular carcinoma (HCC), the most common type of primary liver cancer in India, which sees over 20,000 new cases each year. Occlusafe is part of a cutting-edge therapy known as Balloon-TACE (B-TACE), which increases the precision and effectiveness of TACE by using a balloon to block blood flow during the procedure. LifePearl consists of polyethylene glycol (PEG) embolization microspheres, which can be loaded with chemotherapeutic agents.

In August 2023, TriSalus Life Sciences, a U.S.-based medical technology company focused on oncology, merged with MedTech Acquisition Corporation. This merger is intended to strengthen TriSalus Life Sciences' financial position and support the development of innovative treatments for liver and pancreatic tumors. MedTech Acquisition Corporation is a special purpose acquisition company (SPAC) that targets mergers with existing medical technology firms.

Major players in the liver cancer market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Siemens Healthineers AG, Terumo Corporation, Eisai Co. Ltd., Qiagen N.V., Exelixis Inc., BeiGene Ltd., RayzeBio Inc., Innovent Biologics Inc., Celsion Corporation.

North America was the largest region in the liver cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in liver cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the liver cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Liver cancer is a type of malignant disease that begins in the liver cells, primarily hepatocytes, and has the potential to spread to other organs. It is linked to risk factors such as chronic infections with hepatitis B and C, cirrhosis, excessive alcohol use, and non-alcoholic fatty liver disease (NAFLD). The disease is often diagnosed in its advanced stages, making early detection and treatment essential for improving survival rates.

The main forms of liver cancer include hepatoblastoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and fibrolamellar carcinoma. Hepatoblastoma is a rare form of liver cancer that typically affects young children and arises from immature liver cells. Liver cancer progresses through various stages, including the early, intermediate, and advanced stages. Treatment options include targeted therapy, radiation therapy, surgery, chemotherapy, and immunotherapy. The primary end users of these treatments are hospitals, specialty clinics, ambulatory surgical centers, and cancer research institutes.

The liver cancer market research report is one of a series of new reports that provides liver cancer market statistics, including the liver cancer industry global market size, regional shares, competitors with the liver cancer market share, detailed liver cancer market segments, market trends, and opportunities, and any further data you may need to thrive in the liver cancer industry. This liver cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The liver cancer market consists of revenues earned by entities providing services such as early screening, palliative care, liver transplantation, personalized medicine, and radiofrequency ablation. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver cancer market also includes sales of diagnostic imaging equipment, biomarker tests, embolization devices, and supportive care medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.